Passage Bio Beheer

Hoe is Will Chou's beloning veranderd ten opzichte van Passage Bio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$69m
Jun 30 2024	n/a	n/a	-US$77m
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$1m	US$599k	-US$102m
Sep 30 2023	n/a	n/a	-US$112m
Jun 30 2023	n/a	n/a	-US$112m
Mar 31 2023	n/a	n/a	-US$128m
Dec 31 2022	US$1m	US$112k	-US$136m

Compensatie versus markt: De totale vergoeding ($USD 1.45M ) Will } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Will is gestegen terwijl het bedrijf verliesgevend is.

CEO

Will Chou (51 yo)

2.1yrs

Tenure

US$1,448,546

Compensatie

Dr. William Chou, MD, also known as Will, has been the Chief Executive Officer and Director of Passage Bio, Inc. from October 10, 2022 and serves as its President. Dr. Chou is an accomplished executive wit...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
William Chou	President	2.1yrs	US$1.45m	geen gegevens
Edgar Cale	General Counsel & Company Secretary	5.2yrs	US$804.69k	0.080% $ 30.7k
James Wilson	Co-Founder & Chief Scientific Advisor	no data	geen gegevens	geen gegevens
Kathleen Borthwick	Senior VP	1.3yrs	geen gegevens	0.046% $ 17.7k
Stuart Henderson	Senior Vice President of Corporate Development & Investor Relations	3.8yrs	geen gegevens	geen gegevens
Eden Fucci	Senior Vice President of Technical Operations	1.3yrs	geen gegevens	geen gegevens
Sue Browne	Senior Vice President of Research & Development	less than a year	geen gegevens	geen gegevens
Karl Whitney	Senior Vice President of Global Regulatory Affairs	less than a year	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PASG wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
William Chou	President	2.1yrs	US$1.45m	geen gegevens
Thomas Kassberg	Director	less than a year	geen gegevens	geen gegevens
Maxine Gowen	Independent Chairwoman of the Board	3.8yrs	US$101.34k	0% $ 0
Saqib Islam	Independent Director	5.7yrs	US$65.84k	0.0081% $ 3.1k
Athena Countouriotis	Independent Director	4.8yrs	US$69.97k	0.031% $ 11.7k
Sandip Kapadia	Independent Director	4.9yrs	US$73.34k	0% $ 0
Derrell Porter	Independent Director	3.5yrs	US$69.30k	0% $ 0
Dolan Sondhi	Independent Director	1.3yrs	US$49.90k	0% $ 0

3.6yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PASG wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Passage Bio Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Passage Bio, Inc. Appoints Thomas Kassberg as Class I Director and Member of the Audit Committee of the Board

Passage Bio, Inc., Annual General Meeting, May 21, 2024

Passage Bio, Inc. Announces Executive Changes

High number of new directors

Passage Bio, Inc. Announces Resignation of Maxine Gowen as Interim Executive Chairwoman

Passage Bio, Inc. Announces Executive Changes

Recent updates

Passage Bio, Inc. Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy 31st Annual Conference

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias

Passage Bio, Inc. Appoints Thomas Kassberg as Class I Director and Member of the Audit Committee of the Board

Price target increased by 9.5% to US$7.67

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

New minor risk - Shareholder dilution

Passage Bio, Inc., Annual General Meeting, May 21, 2024

Passage Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Price target increased by 27% to US$7.00

Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Price target decreased by 23% to US$5.40

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Price target decreased by 20% to US$7.00

Passage Bio, Inc. Announces New Interim Safety, Biomarker, and Survival Data from Cohorts 1-4 in Imagine-1 Clinical Study

Passage Bio, Inc. Announces Executive Changes

Price target increased by 9.9% to US$8.17

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Price target increased by 9.3% to US$8.33

Passage Bio, Inc. Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

High number of new directors

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Announces Resignation of Maxine Gowen as Interim Executive Chairwoman

Passage Bio, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Passage Bio, Inc. Announces Executive Changes

Passage appoints William Chou CEO

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

Passage Bio GAAP EPS of -$0.73 beats by $0.09

High number of new directors

Passage Bio, Inc. Appoints Michael Kamarck to Board of Directors

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2000 Dynamic Index

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Passage Bio, Inc. Announces Management Changes

Passage Bio, Inc. Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study At ASGCT 25Th Annual Meeting

Passage Bio, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new directors

Passage Bio, Inc., Annual General Meeting, May 26, 2022

Passage Bio: Worth Keeping An Eye On

Passage Bio, Inc. Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

Passage Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Passage Bio Presents New Interim Clinical Data for Patients with Gm1 Gangliosidosis in Imagine-1 Study At 2022 Worldsymposium

Price target decreased to US$23.38

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio Announces Pipeline Expansion and Clinical Program Update

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2500 Growth Index

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

Independent Director Patrick Heron has left the company

Chief Financial Officer has left the company

Chief Medical Officer has left the company

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

Chief Medical Officer notifies of intention to sell stock

Passage Bio, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Passage Bio, Inc. to Report Q4, 2020 Results on Mar 03, 2021

New 90-day low: US$18.13

Passage Bio, Inc. Announces Board Changes

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations